Dr Bruno Paiva, PharmD, PhD, is a research fellow of the Departments of Haematology and Immunology at the Clinica Universidad de Navarra and CIMA, Pamplona, Spain. He is also the Director of the Flow Cytometry Core of the University of Navarra.

Meral Beksaç MD is a Professor in the Department of Hematology at Ankara University, Turkey. Her current administrative position is Director of the Unrelated Donor Registry and the recently FACT/NETCORD accredited Cord Blood Bank. She has been actively involved in investigator initiated or pharma sponsored Phase II-III clinical trials since 1992, initially within the auspices of EORTC-LCG and most recently in collaboration with European Myeloma Network.

After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr. Paul Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide for the treatment of multiple myeloma.

Dr Nagler received his medical training at the Hebrew University-Hadassah Medical School, Jerusalem, Israel; he then carried out a Postdoctoral research fellowship in hematology and bone marrow transplantation at “Stanford University Hospital” Palo Alto, CA, in the USA, from 1986 to 1990.
Dr Nagler serves on the Board of Directors of Netcord organization of cord blood banks and was the Netcord Threasurer from 2010-2013.

Saad Zafar Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut.

Xavier Leleu, MD, PhD, is Professor, Head of the myeloma clinic and head of the department of Haematology at Hôpital La Mileterie, part of the academic hospital of Poitiers (CHU), France. Dr Leleu received his medical degree at the University of Bordeaux, France.

Dr. Lonial is the department chair for Hematology and Medical Oncology at Emory University, and is the myeloma editor for Clinical Lymphoma and Myeloma and on the editorial board for the Journal of Clinical Oncology He is also an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, Leukemia, and other journals.

Dr Nizar Jacques Bahlis is an associate professor at the Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of Calgary. He is also a member of the Divisions of Hematology and Medical Oncology. Dr Bahlis received his medical degree from St Joseph University – French Faculty of Medicine in Beirut, Lebanon.

Dr Cyrille Touzeau is a hematologist in the Hematology Department from the University Hospital of Nantes, France. He specializes in clinical hematology, with a particular focus on multiple myeloma and its treatment. His PhD was mainly focused on the activity of BH3 mimetics in multiple myeloma. Dr Touzeau is currently a member of the Intergroupe Francophone du Myélome (IFM). Dr Touzeau published more than 80 peer-reviewed publications dedicated to multiple myeloma.

Dr. Enrique M. Ocio, MD, PhD, is the Head of the Hematology Department of the University Hospital “Marqués de Valdecilla” and is the responsible for the Hematology Research group at the IDIVAL Biomedical Research Institute in Santander (Cantabria-Spain). He is also Associate Professor of Medicine in the University of Cantabria.

Dr. Trudel received her MD degree from the Faculty of Medicine at the University of Toronto and subsequently completed subspecialty training in Hematology at the University of Toronto affiliated hospitals. This was followed by a research fellowship at Weil Medical College of Cornell in New York City.